TickerTalks
Browse all tickers →
TickerTalks›$ARCT
ARARCT

Arcturus Therapeutics Holdings Inc.

$ARCT·$394M·Biotechnology·Healthcare
$13.70-5.3%YTD+121.3%1Y-27.1%
Price updated 3h ago·X counts updated 2d ago
ARARCT
$ARCTArcturus Therapeutics Holdings Inc.
$13.70-5.26%788 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $ARCT on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

788X posts · last 7 days
Sep 12Sep 27
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $ARCT's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data9 posts analyzed · as of 2026-09-29

ArcTools ($ARCT) holders are bullish after surpassing ~$200K in volume with a stated target of $1M, framing it as a top-15 project on Arc chain barely two weeks in. Bulls dismiss last night's ecosystem-wide sell-offs as scared money exiting; there's no bear voice inside the window.

Read what X is saying about $ARCT

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $ARCT — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-09-28

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Arcturus just released Phase 2 OTC Deficiency data and unveiled LUNAR 2.0 — real biotech catalyst, and X chatter is tagged to a crypto with the same ticker.

Arcturus Therapeutics is a rare-disease mRNA biotech that just presented Phase 2 interim data for ARCT-810 in Ornithine Transcarbamylase (OTC) Deficiency and unveiled the next-generation LUNAR 2.0 mRNA delivery platform. It's up 124% YTD but still down 32% in a year — the September data readout is what changed the trajectory.

  • The clinical story is what the model runs on: analysts see revenue moving from ~$18M this year to $278M by 2030 (from a very small analyst pool) as ARCT-810 progresses to a potential Phase 3 and LUNAR 2.0 licenses out.
  • The financial cost is still enormous: operating margin at -433%, negative free cash flow of 44% of market cap, and consensus 2026 EPS of -$3.40 — the runway math is what decides whether a Phase 3 readout is even feasible without a big raise.
  • The insider tape is quiet — no filings in the last month, which for a small-cap biotech mid-readout cycle is neutral and provides no incremental signal.

November 9 earnings and any color on ARCT-810 Phase 3 timing plus LUNAR 2.0 partnership pipeline decides the next leg — a named Big Pharma partnership on LUNAR 2.0 restarts the tape decisively; a delayed Phase 3 or another dilutive raise is what turns the coiling into a real drawdown.

What to watch: November 9 earnings — ARCT-810 Phase 3 timing, LUNAR 2.0 partnership pipeline, and cash-runway color; a named Big Pharma partnership on LUNAR 2.0 restarts the tape, a delayed Phase 3 or dilutive raise breaks the coil the wrong way.

On the calendar: 2026-11-09 — Q3 earnings

sentiment wrong asset

Read the AI verdict on $ARCT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

RNA medicines biotech with mRNA vaccine and rare liver/respiratory disease pipeline using its LUNAR lipid nanoparticle delivery platform.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ARCT.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $ARCT

Partial — RNA medicines biotech with mRNA vaccine and rare liver/respiratory disease pipeline using its LUNAR lipid nanoparticle delivery platform.

Top industry ETF

$IBBiShares Biotechnology ETF
+24.4%YTD
+48.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-53.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-433%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-43.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
8.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-46.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
83.2%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.84$-1.00+15.7%
Q1 2026May 7, 2026$-0.95$-1.03+7.4%
Q4 2025Mar 3, 2026$-1.03$-0.92-12.0%
Q3 2025Nov 10, 2025$-0.49$-0.80+38.7%
Next earningsMon, Nov 9·consensus EPS $-0.67

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$3.0M-87.9%100%-863%$-0.84$-39.4M
Q1 FY26$610K-97.9%-7.9%-4882%$-0.95$-19.4M
Q4 FY25$3.1M-85.3%100%-1016%$-1.05$-16.4M
Q3 FY25$17.2M-55.8%80.5%-96.3%$-0.49$-17.3M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$17.9M$7.9M – $26.4M-$3.40-$4.47 – -$2.8810
FY27$20.6M$2.6M – $44.7M-$3.66-$4.94 – -$3.0510
FY28$42.8M$42.7M – $42.8M-$3.43-$4.87 – -$2.5710
FY29$107.5M$26.3M – $310.1M-$1.30-$4.48 – -$0.025
FY30$277.7M$67.9M – $800.8M$2.50$0.04 – $8.615

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.48%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+29.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+72.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 26.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.485-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 8 other (8 awards) in window

See when $ARCT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDSep 238-K — Item 7.01: Press release / Reg FD
AI summary

Arcturus Therapeutics Holdings Inc. (ARCT) presented Phase 2 clinical data for ARCT-810 and provided an update on its mRNA delivery platform at a September 23, 2026 event, with both a press release and a full presentation furnished as exhibits to this Reg FD disclosure. ARCT-810 is Arcturus's mRNA candidate for OTC deficiency. This could be a material catalyst depending on the Phase 2 data disclosed in the attached exhibit.

8-KPress release / Reg FDAug 258-K — Item 7.01: Press release / Reg FD
AI summary

Arcturus Therapeutics (ARCT) furnished an 8-K disclosing that the company is presenting a poster on ARCT-810, its investigational mRNA therapy for ornithine transcarbamylase (OTC) deficiency, at the Society for the Study of Inborn Errors of Metabolism (SSIEM) annual symposium in Helsinki. OTC deficiency is a rare urea cycle disorder, and ARCT-810 represents Arcturus' lead rare disease program using its LUNAR lipid nanoparticle delivery technology. The company also indicated a regulatory plan update for ARCT-810 is expected later in the current quarter. The presentation and upcoming regulatory update are key catalysts for investors tracking this rare disease pipeline.

8-KMaterial agreementJul 28-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

Arcturus Therapeutics (ARCT) entered into a strategic CDMO and CRO collaboration with Thermo Fisher Scientific on June 26, 2026, for the development of ARCT-032, its investigational mRNA therapeutic for cystic fibrosis. Thermo Fisher will contribute up to $40 million in clinical manufacturing services through its Pharma Services division, and Arcturus will engage Thermo Fisher's PPD affiliate for up to $40 million in CRO services. Upon regulatory approval of ARCT-032, Thermo Fisher would receive exclusive commercial manufacturing rights for a specified duration under a definitive supply agreement to be negotiated in good faith. The collaboration is structured through a Master Services Agreement and a Project Addendum for Development Services with Patheon UK Limited.

8-KShareholder voteJun 58-K — Item 5.07: Shareholder vote
3New insider — initial holdingsMay 73
8-KOfficer or director changeMay 78-K — Item 2.02: Earnings release · Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
+ 5 other (2 10-Qs · 1 earnings 8-K · 1 13G · 1 proxy) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

4 RNA Therapeutics Stocks Leading the Next Wave of Innovationzacks.com·2d agoArcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platformmarketbeat.com·5d agoArcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcriptseekingalpha.com·6d agoArcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platformbusinesswire.com·6d agoArcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Programseekingalpha.com·9d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$VKTX$MRNA$RARE$NWBO$AURA$IBRX$NKTR$ABVX
Voices on X · top 8 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport